Sonia Fargue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sonia Fargue has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
John Knight
University of Alabama at Birmingham
10 shared publicationsPierre Cochat
Service de pédiatrie, hôpital Femme–Mère-Enfant, hospices civils de Lyon, 59, boulevard Pinel, 69677 Bron cedex, France
8 shared publicationsChristopher J. Danpure
Department of Cell & Developmental Biology, University College London, London WC1E 6BT, UK
7 shared publicationsJérôme Harambat
Department of Pediatrics, Bordeaux University Hospital, Bordeaux, France
7 shared publicationsKyle D. Wood
Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA
6 shared publicationsDean G. Assimos
University of Alabama at Birmingham
5 shared publications
Latest Publications
- 1 June 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 330 (6) , F702-F711
Endogenous oxalate synthesis in mouse models of metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) has been reported to lead to increased oxalate synthesis in mouse models. We show here that changes in oxalate synthesis, mediated by complex changes in enzymes involved in glyoxylate metabolism, are dependent on the degree of severity of MASLD, resulting in limited increases in urinary oxalate in mild MASLD, but marked increases in steatohepatitis.
- 1 June 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 330 (6) , F702-F711
Endogenous oxalate synthesis in mouse models of metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) has been reported to lead to increased oxalate synthesis in mouse models. We show here that changes in oxalate synthesis, mediated by complex changes in enzymes involved in glyoxylate metabolism, are dependent on the degree of severity of MASLD, resulting in limited increases in urinary oxalate in mild MASLD, but marked increases in steatohepatitis.
- Open Access
- 21 August 2025
- Published by SAGE Publications in Journal of Endourology
- Vol. 39 (8) , 815-821
Factors Influencing Oxalate Synthesis in Healthy Volunteers
Introduction: Urine oxalate excretion influences the risk of calcium oxalate kidney stone formation and has been reported to positively correlate with body mass index (BMI) and body weight. The two major sources of urine oxalate are dietary oxalate absorption and endogenous oxalate synthesis (EOS). In this study, we investigated the association between EOS, as estimated by oxalate content of 24-hour urine collected while consuming an ultra-low oxalate diet, and measures of body size and composition. Methods: An analysis of prospectively performed studies conducted on adults consuming ultra-low oxalate diets between January 2018 and January 2025 at the University of Alabama at Birmingham was undertaken. All participants ( n = 88) were healthy and had no history of kidney stone disease, hypertension, or diabetes. Participants underwent anthropomorphic measurements, and body composition was measured by bioelectrical impedance analysis. Urinary oxalate was measured by ion chromatography coupled to mass spectrometry. Results: Total urinary oxalate was positively correlated with body weight, BMI, lean body muscle mass, appendicular lean muscle mass, waist-to-hip ratio, and urinary creatinine excretion. There was no significant correlation between urinary oxalate excretion and body fat or age. Urinary oxalate excretion was different in males and females, even after adjusting for measures of lean body composition. Discussion: This analysis of low oxalate controlled diet studies in healthy participants suggests lean body mass, not body fat, is the major driver of EOS. This study also highlights that oxalate synthesis in lean body compartments is different in males and females.
- 21 August 2025
- Published by SAGE Publications in Journal of Endourology
- Vol. 39 (8) , 815-821
Open AccessFactors Influencing Oxalate Synthesis in Healthy Volunteers
Introduction: Urine oxalate excretion influences the risk of calcium oxalate kidney stone formation and has been reported to positively correlate with body mass index (BMI) and body weight. The two major sources of urine oxalate are dietary oxalate absorption and endogenous oxalate synthesis (EOS). In this study, we investigated the association between EOS, as estimated by oxalate content of 24-hour urine collected while consuming an ultra-low oxalate diet, and measures of body size and composition. Methods: An analysis of prospectively performed studies conducted on adults consuming ultra-low oxalate diets between January 2018 and January 2025 at the University of Alabama at Birmingham was undertaken. All participants ( n = 88) were healthy and had no history of kidney stone disease, hypertension, or diabetes. Participants underwent anthropomorphic measurements, and body composition was measured by bioelectrical impedance analysis. Urinary oxalate was measured by ion chromatography coupled to mass spectrometry. Results: Total urinary oxalate was positively correlated with body weight, BMI, lean body muscle mass, appendicular lean muscle mass, waist-to-hip ratio, and urinary creatinine excretion. There was no significant correlation between urinary oxalate excretion and body fat or age. Urinary oxalate excretion was different in males and females, even after adjusting for measures of lean body composition. Discussion: This analysis of low oxalate controlled diet studies in healthy participants suggests lean body mass, not body fat, is the major driver of EOS. This study also highlights that oxalate synthesis in lean body compartments is different in males and females.
- Open Access
- 13 February 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (5) , 1518-1528
Inducing Oxalobacter formigenes Colonization Reduces Urinary Oxalate in Healthy Adults
- 13 February 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (5) , 1518-1528
Open AccessInducing Oxalobacter formigenes Colonization Reduces Urinary Oxalate in Healthy Adults
- Open Access
- 28 June 2024
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 39, 101765
4-hydroxy-2-oxoglutarate metabolism in a mouse model of Primary Hyperoxaluria Type 3
- 28 June 2024
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 39, 101765
Open Access4-hydroxy-2-oxoglutarate metabolism in a mouse model of Primary Hyperoxaluria Type 3
- 14 June 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (9) , 1505-1507
Endogenous Oxalate Synthesis and Urinary Oxalate Excretion
An abstract is unavailable. This article is available as a PDF only.
- 14 June 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (9) , 1505-1507
Endogenous Oxalate Synthesis and Urinary Oxalate Excretion
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 17 May 2022
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 15 (Supplement) , i4-i8
Primary hyperoxaluria type 1: pathophysiology and genetics
Primary hyperoxaluria type 1 (PH1) is a rare genetic form of calcium oxalate kidney stone disease. It is caused by a deficiency in the liver-specific enzyme, alanine:glyoxylate aminotransferase (AGT), a pyridoxal-5′-phosphate (PLP)-dependent enzyme involved in the metabolism of glyoxylate. The excessive endogenous synthesis of oxalate that ensues leads to hyperoxaluria, and the crystallization of the poorly soluble calcium salt of oxalate is responsible for a severe kidney stone disease, which can progress to end-stage renal disease, systemic deposition of oxalate and death. Knowledge about metabolic precursors of glyoxylate and oxalate, molecular pathology of AGT and analytical methods for diagnosis and clinical assessment have allowed a better understanding of the mechanisms underlying PH1 and opened the door to new therapeutic strategies.
- 17 May 2022
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 15 (Supplement) , i4-i8
Open AccessPrimary hyperoxaluria type 1: pathophysiology and genetics
Primary hyperoxaluria type 1 (PH1) is a rare genetic form of calcium oxalate kidney stone disease. It is caused by a deficiency in the liver-specific enzyme, alanine:glyoxylate aminotransferase (AGT), a pyridoxal-5′-phosphate (PLP)-dependent enzyme involved in the metabolism of glyoxylate. The excessive endogenous synthesis of oxalate that ensues leads to hyperoxaluria, and the crystallization of the poorly soluble calcium salt of oxalate is responsible for a severe kidney stone disease, which can progress to end-stage renal disease, systemic deposition of oxalate and death. Knowledge about metabolic precursors of glyoxylate and oxalate, molecular pathology of AGT and analytical methods for diagnosis and clinical assessment have allowed a better understanding of the mechanisms underlying PH1 and opened the door to new therapeutic strategies.
- Open Access
Contribution of Dietary Oxalate and Oxalate Precursors to Urinary Oxalate Excretion
Kidney stone disease is increasing in prevalence, and the most common stone composition is calcium oxalate. Dietary oxalate intake and endogenous production of oxalate are important in the pathophysiology of calcium oxalate stone disease. The impact of dietary oxalate intake on urinary oxalate excretion and kidney stone disease risk has been assessed through large cohort studies as well as smaller studies with dietary control. Net gastrointestinal oxalate absorption influences urinary oxalate excretion. Oxalate-degrading bacteria in the gut microbiome, especially Oxalobacter formigenes, may mitigate stone risk through reducing net oxalate absorption. Ascorbic acid (vitamin C) is the main dietary precursor for endogenous production of oxalate with several other compounds playing a lesser role. Renal handling of oxalate and, potentially, renal synthesis of oxalate may contribute to stone formation. In this review, we discuss dietary oxalate and precursors of oxalate, their pertinent physiology in humans, and what is known about their role in kidney stone disease.
Open AccessContribution of Dietary Oxalate and Oxalate Precursors to Urinary Oxalate Excretion
Kidney stone disease is increasing in prevalence, and the most common stone composition is calcium oxalate. Dietary oxalate intake and endogenous production of oxalate are important in the pathophysiology of calcium oxalate stone disease. The impact of dietary oxalate intake on urinary oxalate excretion and kidney stone disease risk has been assessed through large cohort studies as well as smaller studies with dietary control. Net gastrointestinal oxalate absorption influences urinary oxalate excretion. Oxalate-degrading bacteria in the gut microbiome, especially Oxalobacter formigenes, may mitigate stone risk through reducing net oxalate absorption. Ascorbic acid (vitamin C) is the main dietary precursor for endogenous production of oxalate with several other compounds playing a lesser role. Renal handling of oxalate and, potentially, renal synthesis of oxalate may contribute to stone formation. In this review, we discuss dietary oxalate and precursors of oxalate, their pertinent physiology in humans, and what is known about their role in kidney stone disease.
- 28 September 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1867 (1) , 165981
Effect of alanine supplementation on oxalate synthesis
- 28 September 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1867 (1) , 165981
Effect of alanine supplementation on oxalate synthesis
- 12 March 2020
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 15 (7) , 1056-1065
End Points for Clinical Trials in Primary Hyperoxaluria
Patients with primary hyperoxaluria experience kidney stones from a young age and can develop progressive oxalate nephropathy. Progression to kidney failure often develops over a number of years, and is associated with systemic oxalosis, intensive dialysis, and often combined kidney and liver transplantation. There are no therapies approved by the Food and Drug Association. Thus, the Kidney Health Initiative, in partnership with the Oxalosis and Hyperoxaluria Foundation, initiated a project to identify end points for clinical trials. A workgroup of physicians, scientists, patients with primary hyperoxaluria, industry, and United States regulators critically examined the published literature for clinical outcomes and potential surrogate end points that could be used to evaluate new treatments. Kidney stones, change in eGFR, urine oxalate, and plasma oxalate were the strongest candidate end points. Kidney stones affect how patients with primary hyperoxaluria feel and function, but standards for measurement and monitoring are lacking. Primary hyperoxaluria registry data suggest that eGFR decline in most patients is gradual, but can be unpredictable. Epidemiologic data show a strong relationship between urine oxalate and long-term kidney function loss. Urine oxalate is reasonably likely to predict clinical benefit, due to its causal role in stone formation and kidney damage in CKD stages 1–3a, and plasma oxalate is likely associated with risk of systemic oxalosis in CKD 3b–5. Change in slope of eGFR could be considered the equivalent of a clinically meaningful end point in support of traditional approval. A substantial change in urine oxalate as a surrogate end point could support traditional approval in patients with primary hyperoxaluria type 1 and CKD stages 1–3a. A substantial change in markedly elevated plasma oxalate could support accelerated approval in patients with primary hyperoxaluria and CKD stages 3b–5. Primary hyperoxaluria type 1 accounts for the preponderance of available data, thus heavily influences the conclusions. Addressing gaps in data will further facilitate testing of promising new treatments, accelerating improved outcomes for patients with primary hyperoxaluria.
- 12 March 2020
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 15 (7) , 1056-1065
End Points for Clinical Trials in Primary Hyperoxaluria
Patients with primary hyperoxaluria experience kidney stones from a young age and can develop progressive oxalate nephropathy. Progression to kidney failure often develops over a number of years, and is associated with systemic oxalosis, intensive dialysis, and often combined kidney and liver transplantation. There are no therapies approved by the Food and Drug Association. Thus, the Kidney Health Initiative, in partnership with the Oxalosis and Hyperoxaluria Foundation, initiated a project to identify end points for clinical trials. A workgroup of physicians, scientists, patients with primary hyperoxaluria, industry, and United States regulators critically examined the published literature for clinical outcomes and potential surrogate end points that could be used to evaluate new treatments. Kidney stones, change in eGFR, urine oxalate, and plasma oxalate were the strongest candidate end points. Kidney stones affect how patients with primary hyperoxaluria feel and function, but standards for measurement and monitoring are lacking. Primary hyperoxaluria registry data suggest that eGFR decline in most patients is gradual, but can be unpredictable. Epidemiologic data show a strong relationship between urine oxalate and long-term kidney function loss. Urine oxalate is reasonably likely to predict clinical benefit, due to its causal role in stone formation and kidney damage in CKD stages 1–3a, and plasma oxalate is likely associated with risk of systemic oxalosis in CKD 3b–5. Change in slope of eGFR could be considered the equivalent of a clinically meaningful end point in support of traditional approval. A substantial change in urine oxalate as a surrogate end point could support traditional approval in patients with primary hyperoxaluria type 1 and CKD stages 1–3a. A substantial change in markedly elevated plasma oxalate could support accelerated approval in patients with primary hyperoxaluria and CKD stages 3b–5. Primary hyperoxaluria type 1 accounts for the preponderance of available data, thus heavily influences the conclusions. Addressing gaps in data will further facilitate testing of promising new treatments, accelerating improved outcomes for patients with primary hyperoxaluria.
- 1 September 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (9) , 2203-2209
Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity
- 1 September 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (9) , 2203-2209
Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity